Rekvina Laboratories
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
This data is currently unavailable for this company.
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Rekvina Laboratories do?
Rekvina Laboratories Ltd is committed to provide quality medication at affordable prices to the patients with a view to help bring down the healthcare costs.
Who are the competitors of Rekvina Laboratories?
Rekvina Laboratories major competitors are Hamps Bio, Venmax Drugs&Pharma, Adeshwar Meditex, Cian Healthcare, Kobo Biotech, Ishita Drugs & Inds., Unick Fix-A-Form. Market Cap of Rekvina Laboratories is ₹22 Crs. While the median market cap of its peers are ₹21 Crs.
Is Rekvina Laboratories financially stable compared to its competitors?
Rekvina Laboratories seems to be less financially stable compared to its competitors. Altman Z score of Rekvina Laboratories is -0.47 and is ranked 8 out of its 8 competitors.
Does Rekvina Laboratories pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Rekvina Laboratories latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Rekvina Laboratories allocated its funds?
Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments, Short Term Loans & Advances
How strong is Rekvina Laboratories balance sheet?
Rekvina Laboratories balance sheet is weak and might have solvency issues
Is the profitablity of Rekvina Laboratories improving?
No, profit is decreasing. The profit of Rekvina Laboratories is -₹0.14 Crs for Mar 2025, -₹0.02 Crs for Mar 2024 and ₹0 Crs for Mar 2023
Is the debt of Rekvina Laboratories increasing or decreasing?
Yes, The net debt of Rekvina Laboratories is increasing. Latest net debt of Rekvina Laboratories is ₹1.46 Crs as of Mar-26. This is greater than Mar-25 when it was ₹0.2 Crs.
Is Rekvina Laboratories stock expensive?
There is insufficient historical data to gauge this. Latest PE of Rekvina Laboratories is 0
Has the share price of Rekvina Laboratories grown faster than its competition?
Rekvina Laboratories has given better returns compared to its competitors. Rekvina Laboratories has grown at ~401.41% over the last 1yrs while peers have grown at a median rate of -9.37%
Is the promoter bullish about Rekvina Laboratories?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Rekvina Laboratories is 41.3% and last quarter promoter holding is 41.3%.
Are mutual funds buying/selling Rekvina Laboratories?
There is Insufficient data to gauge this.